Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9026453 | 0.93 | CYP4F2 (0.49) | CYP4A11CYP4F2GABRA1GABRB2LIPG | |
| SCHEMBL3827720 | 0.91 | LIPG (0.48) | CYP4A11CYP4F2GABRA1GABRB2LIPG | |
| SCHEMBL29681353 | 0.88 | TDP1 (0.43) | CYP4A11CYP4F2LIPGPOLBKDM4E | |
| SCHEMBL1607140 | 0.88 | TDP1 (0.43) | CYP4A11CYP4F2LIPGPOLBKDM4E | |
| SCHEMBL29681348 | 0.88 | TDP1 (0.43) | CYP4A11CYP4F2LIPGPOLBKDM4E | |
| SCHEMBL12634509 | 0.86 | LIPG (0.52) | CYP4A11CYP4F2LIPG | |
| SCHEMBL13552185 | 0.86 | LIPG (0.47) | CYP4A11CYP4F2LIPGPOLBKDM4E | |
| SCHEMBL3022571 | 0.86 | GABRA1 (0.48) | CYP4A11CYP4F2GABRA1GABRB2MGLL | |
| SCHEMBL3271303 | 0.84 | LIPG (0.60) | CYP4A11CYP4F2LIPG | |
| SCHEMBL27292 | 0.81 | CYP4F2 (0.49) | CYP4A11CYP4F2LIPGPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268568-A4 | NO VOC RADIATION CURABLE RESIN COMPOSITIONS | FOSTER MILLER INC (US) | 2003-05-28 | — | — | EP | claimed |
| EP-1268568-A1 | NO VOC RADIATION CURABLE RESIN COMPOSITIONS | FOSTER MILLER, INC. (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2001060870-A1 | NO VOC RADIATION CURABLE RESIN COMPOSITIONS | FOSTER MILLER, INC. (US) | 2001-08-23 | — | — | WO | claimed |
| EP-2861571-B1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-05-03 | — | — | EP | disclosed |
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | CYP4A11 1493/4885CYP4F2 1875/4885GABRA1 1360/4885 |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | CYP4A11 389/4885CYP4F2 281/4885GABRA1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.